In the largest study to date for Crohn's disease, researchers from the Wellcome Sanger Institute and the Broad Institute of MIT and Harvard identified rare variants of 10 genes associated with this pathology. The researchers sequenced the exomes of 110,000 people, 30,000 patients with Crohn's and 80,000 without this condition, with the participation of a hundred international scientific institutions. Read More
Biodol Therapeutics, a portfolio company of V-Bio Ventures, has nominated its first preclinical candidate for neuropathic pain. The candidate is a small-molecule allosteric FLT3 inhibitor, suitable for chronic oral administration and without the safety limitations of less specific intracellular kinase inhibitors. Read More
There is a lack of biomarkers for disease activity in aortic stenosis (AS). On the other hand, citrullination is involved in many chronic inflammatory processes and citrullinated proteins have been found within atherosclerotic plaque. Read More
The crosstalk between immune cells and multiple myeloma (MM) cells is an important determinant of MM progression, but the mechanisms behind this have not been fully defined. Read More
Researchers from University Hospital Bonn presented data from a study that aimed to evaluate the significance of serum levels of the endoplasmic-reticulum-stress chaperone GRP78 in patients undergoing coronary angiography for suspected coronary artery disease (CAD). Read More
Atrial fibrillation (AF) is a very common diagnosed arrhythmia and catheter ablation is an effective treatment, but recurrence occurs after catheter ablation and remains a medical challenge. MicroRNAs can be easily detected in the circulation, and they are epigenetic regulators in many biological processes; their usefulness as biomarkers of risk stratification in patients with AF was investigated. Read More
Amgen Inc. has described tricyclic-amido-bicyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. Read More
Black Diamond Therapeutics Inc. has patented quinoxaline derivatives acting as fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer. Read More
Eikonizo Therapeutics Inc. has identified histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders, among others. Read More
T2YC Co. Ltd. has synthesized benzimidazoles acting as protein ENL inhibitors reported to be useful for the treatment of acute myeloid leukemia. Read More
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Read More
Mas-related G-protein coupled receptor X2 (MRGPRX2) is expressed particularly on mast cells and its activation leads to the mast cell degranulation with release of inflammatory mediators. Read More
MC2 Therapeutics A/S has discovered that carbamylation of proteins, peptides and amino acids in the skin, caused by isocyanate, may be the root cause of several urea-associated skin diseases, such as chronic kidney disease-associated pruritus (CKD-aP, or uremic pruritus) and genital lichen sclerosus. Read More
Arcturus Therapeutics Inc. has obtained an award for up to US$63.2 million from the Biomedical Advanced Research and Development Authority (BARDA) to expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform. Read More
Circadian rhythm disorders are associated with psychiatric disorders including depression, bipolar disease and schizophrenia. To target casein kinase I isoform delta (CKI-delta), Janssen Pharmaceutica NV scientists sought potent, selective, brain-penetrant CKI-delta inhibitors which can be dosed daily and orally. Read More
Researchers from Pfizer Inc. presented preclinical data for the melanocortin MC4 receptor (MC4R) antagonist PF-07258669, being developed for the treatment of anorexia nervosa. Read More
